Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Harbour BioMed Announces $140 Million Deal to Out-license Autoimmune Therapy to CSPC

publication date: Oct 12, 2022

Harbour BioMed out-licensed Greater China rights for an autoimmune therapy to CSPC NBP Pharma in a deal worth up to $140 million, including $21 million upfront, plus royalties. NBP will be responsible for China clinical development, commercialization and manufacturing of batoclimab. The candidate is an anti-FcRn monoclonal antibody that accelerates the degradation of autoantibodies to treat pathogenic IgG-mediated autoimmune diseases. In 2017, Harbour acquired China rights to batoclimab in a two candidate deal from Korea’s HanAll Biopharma for $81 million. Harbour has started a China Phase III trial for batoclimab in myasthenia gravis patients. More details....

Stock Symbol: (HK: 02142)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here